ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · Real-Time Price · USD
8.98
-0.41 (-4.37%)
At close: Oct 29, 2025, 4:00 PM EDT
9.04
+0.06 (0.67%)
After-hours: Oct 29, 2025, 6:52 PM EDT
ARS Pharmaceuticals Employees
As of December 31, 2024, ARS Pharmaceuticals had 160 total employees, including 155 full-time and 5 part-time employees. The number of employees increased by 134 or 515.38% compared to the previous year.
Employees
160
Change (1Y)
134
Growth (1Y)
515.38%
Revenue / Employee
$702,119
Profits / Employee
-$300,106
Market Cap
887.46M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 160 | 134 | 515.38% |
| Dec 31, 2023 | 26 | 6 | 30.00% |
| Dec 31, 2022 | 20 | 11 | 122.22% |
| Dec 31, 2021 | 9 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SPRY News
- 21 days ago - ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy® (epinephrine nasal spray) - GlobeNewsWire
- 4 weeks ago - ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy® - GlobeNewsWire
- 5 weeks ago - ARS Pharmaceuticals: A Significant Upside Is Expected From neffy - Seeking Alpha
- 6 weeks ago - ADARx Pharmaceuticals Appoints Industry Veteran, Laura Shawver, Ph.D., as Board Chair - GlobeNewsWire
- 7 weeks ago - Real-World Evidence Supports Clinical Effectiveness of neffy® (epinephrine nasal spray) in Patients Experiencing Anaphylaxis - GlobeNewsWire
- 2 months ago - ARS Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - ARS Pharmaceuticals, Inc. (SPRY) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy® (epinephrine nasal spray) - GlobeNewsWire